Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4559 On Other Exchanges
Symbol
Exchange
4559 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

zeria pharmaceutical co ltd (4559) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZERIA PHARMACEUTICAL CO LTD (4559)

Related News

No related news articles were found.

zeria pharmaceutical co ltd (4559) Related Businessweek News

No Related Businessweek News Found

zeria pharmaceutical co ltd (4559) Details

Zeria Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents. The company also provides cosmetics, health foods, alcoholic beverages, carbonated beverages, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, measuring equipment, and analytical equipment. Its ethical pharmaceutical products include functional dyspepsia treatment products, histamine h2 receptor antagonists, zinc containing anti-ulcerants, oral bowel cleansing products, laxative products, ulcerative colitis remedies, and proton pump inhibitors in the gastrointestinal field. The company’s products also include hypophosphatemia treatment products, long-acting calcium channel blockers, absorbable topical hemostats, sclerotherapy products for leg varicose veins, enzymatic hemostatics, anti-platelet oral jellies, oral non-steroidal anti-inflammatory products, anti-leukopenia after radiotherapy products, topical non-steroidal anti-inflammatory products, anti-inflammatory topical blood circulation enhancers, and non-steroidal anti-inflammatory ophthalmic solutions. In addition, Zeria Pharmaceutical Co., Ltd. offers OTC drugs and products, such as self-prevention products, remedies for gastrointestinal diseases, dermal remedies/cosmeceuticals, ophthalmic solutions, cold remedies, nutrient tonics, and topical anti-inflammatory analgesics. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.

1,426 Employees
Last Reported Date: 06/26/15
Founded in 1955

zeria pharmaceutical co ltd (4559) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zeria pharmaceutical co ltd (4559) Key Developments

Zeria Mulls Acqusitions

Zeria Pharmaceutical Co., Ltd. (TSE:4559) is seeking acquisitions. Sachiaki Ibe, Chairman and Vhief Executive Officer of Zeria, said, "We are excited to obtain a well-established brand such as Entocort and to expand its commercial reach to Japan and other countries. With this move, we confirm our expansion strategy of organic growth combined with merger and acquisition activities, while delivering increased value to our shareholders."

Zeria Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2015

Zeria Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2015.

Zeria Pharmaceutical Co., Ltd. Announces Yearend Dividend for the Fiscal Year Ended March 31, 2015, Payable on June 29, 2015; Provides Second Quarter and Yearend Dividend Guidance for the Fiscal Year Ending March 31, 2016; Reports Consolidated and Non-Consolidated Unaudited Earnings Results for the Year Ended March 31, 2015; Provides Earnings Guidance for the Six Months and Full Year of Fiscal 2016

Zeria Pharmaceutical Co., Ltd. announced year-end dividend of ¥15.00 per share for the fiscal year ended March 31, 2015 compared to ¥15.00 per share paid a year ago, payable on June 29, 2015. For the fiscal year ending March 31, 2016, the company expects to pay yearend dividend of ¥15.00 per share. For the second quarter of fiscal year ending March 31, 2016, the company expects to pay a dividend of ¥15.00 per share. The company reported consolidated and non-consolidated unaudited earnings results for the year ended March 31, 2015. For the period, on consolidated basis the company reported revenue of ¥61,012 million, operation income of ¥2,678 million, ordinary income of ¥2,770 million, profit net income of ¥2,557 million or 48.15 sen diluted per share as compared to revenue of ¥61,996 million, operation income of ¥6,790 million, ordinary income of ¥6,803 million, profit net income of ¥5,277 million or 115.01 sen diluted per share for the same period last year. Cash flows from operating activities were ¥653 million compared with ¥6,573 million for the same period last year. For the quarter, on non-consolidated basis the company reported revenue of ¥48,872 million, operation income of ¥587 million, ordinary income of ¥1,733 million, profit net income of ¥2,292 million or 43.16 sen diluted per share as compared to revenue of ¥52,075 million, operation income of ¥4,394 million, ordinary income of ¥5,250 million, profit net income of ¥4,245 million or 92.53 sen diluted per share for the same period last year. The company provided earnings guidance for the six months and full year of fiscal 2016. For the second quarter, the company expected revenue of ¥31,000 million, operation income of ¥1,500 million, ordinary income of ¥1,000 million, profit attributable to owners of parent of ¥800 million or 15.06 sen diluted per share. For the full year of fiscal 2016, the company expected revenue of ¥65,000 million, operation income of ¥4,000 million, ordinary income of ¥3,500 million, profit attributable to owners of parent of ¥3,000 million or 56.48 sen diluted per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4559:JP ¥1,814.00 JPY +3.00

4559 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4559.
View Industry Companies
 

Industry Analysis

4559

Industry Average

Valuation 4559 Industry Range
Price/Earnings 36.5x
Price/Sales 1.5x
Price/Book 1.5x
Price/Cash Flow 36.5x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZERIA PHARMACEUTICAL CO LTD, please visit www.zeria.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.